Search

Your search keyword '"Doherty, Alan"' showing total 27 results

Search Constraints

Start Over You searched for: Author "Doherty, Alan" Remove constraint Author: "Doherty, Alan" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
27 results on '"Doherty, Alan"'

Search Results

1. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received

2. Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study

3. A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial

4. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial

5. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

6. Radiotherapy for Prostate Cancer: is it ‘what you do’ or ‘the way that you do it’? A UK Perspective on Technique and Quality Assurance

7. Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment

8. Erratum to ‘Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received’ [European Urology 77 (2020) 320–330]

9. Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).

10. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received

11. Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial

12. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT

13. The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer

14. A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk

15. Additional file 5: of Intragenic sequences in the trophectoderm harbour the greatest proportion of methylation errors in day 17 bovine conceptuses generated using assisted reproductive technologies

16. Additional file 4: of Intragenic sequences in the trophectoderm harbour the greatest proportion of methylation errors in day 17 bovine conceptuses generated using assisted reproductive technologies

17. Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study

18. A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial

20. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

22. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

23. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

24. Radiotherapy for Prostate Cancer: is it ‘what you do’ or ‘the way that you do it’? A UK Perspective on Technique and Quality Assurance

25. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy

27. Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.

Catalog

Books, media, physical & digital resources